<?xml version="1.0" encoding="UTF-8"?>
<p>The newest class of hypoglycemic drugs is the incretin mimetics class, a group of injectable drugs for treatment of type 2 diabetes. They work by mimicking the functions of natural gastrointestinal peptide hormones (incretin) that act principally on pancreatic Î²-cells. Incretin mimetics delay gastric emptying, increase glucose-induced insulin secretion, inhibit the release of glucagon, and stimulate beta cell proliferation [
 <xref rid="B31-jof-07-00058" ref-type="bibr">31</xref>]. The later effect holds promise to counter the gradually failing pancreatic functional mass characteristic of type 2 diabetes. The most common side-effects reported are headache, nasopharyngitis, and upper respiratory tract infection [
 <xref rid="B32-jof-07-00058" ref-type="bibr">32</xref>]. Major safety concerns with incretin-based therapies include the effect of these drugs on pancreatic and thyroid tissue, since animal studies have indicated an association of these drugs with pancreatitis, pancreatic cancer and thyroid carcinoma [
 <xref rid="B33-jof-07-00058" ref-type="bibr">33</xref>].
</p>
